(Report ID: 54087) Drug interactions analysis of: Vioxx, Dilantin, Tylenol (caplet), Avapro, Toprol-xlMany drug interactions and side effects can not be detected until the drugs have been used by millions of people, and for a long time. Large, long-term drug safety studies are ideal to discover these real-world drug outcomes. For the first time, eHealthMe enables health professionals and patients to conduct these studies for their drugs. Click here to check your drugs now, in a whole new way. As of Nov, 21, 2008, eHealthMe analyzes 10,180,643 drug interactions and side effects of 21,667 FDA-approved drugs from 1977 to the present. Results on Nov, 21, 2008: 4 relevant incidents-Avapro-T_general_trend_54087.png)
Note:
- The incidents can not include all actual occurrences
- Data of 2008 is not complete
DISCLAIMER: All adverse drug reaction material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk. Basic information:
| Report ID | Date of submission | Patient age | Patient gender |
| 54087 | Feb, 24, 2006 | 56 | Female |
List of drugs the patient takes:
| Drug |
Vioxx |
Dilantin |
Tylenol (caplet) |
Avapro |
Toprol-xl |
List of drug interactions, adverse side effects / events the patient has:
| Name |
Hypertension |
Myocardial Infarction |
Oedema Peripheral |
Thrombosis |
Results from eHealthMe: 4 relevent incidents1) Comparison with the patient's adverse outcomes:
| Name | Count (% of total reports) |
Hypertension | 1 (25.00%) |
Myocardial Infarction | 4 (100.00%) |
Oedema Peripheral | 1 (25.00%) |
Thrombosis | 1 (25.00%) |
2) Top drug interactions, adverse side effects reported for the past 12 months:
3) Top co-used drugs drugs reported for the past 12 months:
4) Top drug interactions, adverse side effects reported of all time:Death: 0 Cancer: 0
| Name | Count (% of total reports) |
1 | Myocardial Infarction | 4 (100.00%) |
2 | Gastrointestinal Haemorrhage | 2 (50.00%) |
3 | Intervertebral Disc Protrusion | 1 (25.00%) |
4 | Dementia | 1 (25.00%) |
5 | Overdose | 1 (25.00%) |
6 | Depression | 1 (25.00%) |
7 | Sick Sinus Syndrome | 1 (25.00%) |
8 | Aortic Aneurysm | 1 (25.00%) |
9 | Acute Coronary Syndrome | 1 (25.00%) |
10 | Delirium | 1 (25.00%) |
5) Top co-used drugs drugs reported of all time:
| Name | Count |
1 | Nexium | 2 |
2 | Norvasc | 2 |
3 | Aricept | 2 |
4 | Lipitor | 2 |
5 | Prozac | 2 |
6 | Imodium | 2 |
7 | Avalide | 2 |
8 | Ativan | 2 |
9 | Evista | 2 |
10 | Synthroid | 1 |
Want to have a risk analysis report like this for your drugs? Click here. ADVERTISEMENT
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Recent drug risk analysis reports:
Citalopram Hydrobromide (Actavis Eliz... for Depression (Nov, 21, 2008)
|
Prednisone (Cadista Pharms) - 1MG for COPD (Nov, 21, 2008)
|
Side effects comparison of Serevent (Glaxosmithkline) - EQ 0.021... (Nov, 21, 2008)
|
Valium (Roche) - 10MG for Muscle Spasms (Nov, 21, 2008)
|
Aciphex (Eisai Medcl Res) - 20MG for Indegestion (Nov, 21, 2008)
|
Bayer Extra Strength Aspirin For Migr... for CAD (Nov, 21, 2008)
|
Side effects comparison of Wellbutrin Sr (Glaxosmithkline) - 150MG (Nov, 21, 2008)
|
Meloxicam (Actavis Totowa) - 7.5MG for Fibromyalgia (Nov, 21, 2008)
|
Ramipril (Actavis Elizabeth) - 1.25MG for Blood Pressure (Nov, 21, 2008)
|
Side effects comparison of Adderall 20 (Duramed Res) - 5MG;5MG;5... (Nov, 21, 2008)
|
|
|
|
 |
|
How to use the report?
Bring a copy of this report to a doctor's appointment to ensure drug risks are fully discussed and understood, in the process of risk and benefit assessment.
|
 |
|
ADVERTISEMENT
|
|